Elexacaftor, Tezacaftor, and Ivacaftor

Elexacaftor Tezacaftor & Ivacaftor
Generic Name/API:Elexacaftor, Tezacaftor, and Ivacaftor
Packaging:For Tablets: 4 weekly blister wallets, each with 21 tablets-14 for morning (elexacaftor, tezacaftor, ivacaftor) and 7 for evening (ivacaftor). For Sachets: 4 weekly wallets, each with 14 sachets-7 for morning (elexacaftor, tezacaftor, ivacaftor) and 7 for evening (ivacaftor).
Storage:Store at 2ºC to 8ºC (36ºF to 46ºF)
Dosage:For dosage information, please check the General Information section.
Strength:For tablets,Fixed-dose combination containing elexacaftor 50 mg, tezacaftor 25 mg and ivacaftor 37.5 mg co-packaged with ivacaftor 75 mg. For oral granules,Fixed-dose combination containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packaged with ivacaftor 150 mg.
Indication:Trikafta is a prescription medicine used to treat cystic fibrosis (CF) in patients aged 2 years and older with at least one F508del mutation in the CFTR gene. It combines three drugs—elexacaftor, tezacaftor, and ivacaftor—that help the defective CFTR protein work better. This improves lung function, reduces mucus buildup, and decreases the frequency of lung infections. Trikafta has significantly improved the quality of life for many people with CF and is considered a major breakthrough in treatment.

Trikafta (Elexacaftor Tezacaftor & Ivacaftor) is a medication which is used to treat cystic fibrosis (CF) in patients aged 2 years and older. It is designed for people with at least one F508del mutation or another responsive CFTR gene mutation. The medicine combines three drugs: elexacaftor, tezacaftor, and ivacaftor. These drugs work together to improve the function of the faulty CFTR protein. It is considered a major breakthrough in the treatment of cystic fibrosis.

Strength: 

Tablets

  • Fixed dose combination containing elexacaftor 50mg, Tezacaftor 25mg and ivacaftor 37.5mg co-packed with ivacaftor 75mg.
  • Fixed-dose combination containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packed with ivacaftor 150 mg.

Oral Granules

  • Fixed-dose combination oral granules containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packaged with ivacaftor 75 mg oral granules.
  • Fixed-dose combination oral granules containing elexacaftor 80 mg, tezacaftor 40 mg, and ivacaftor 60 mg co-packaged with ivacaftor 59.5 mg oral granules.

Dosage: 

Recommended dosage for Trikafta in Adults and Pediatric Patients Aged 2 Years and Older  are as follows: 

Age  Weight Morning dose  Evening dose 
2 to less than 6 years Less than 14 kg One packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) oral granules  One packet (containing ivacaftor 59.5 mg) oral granules
14 kg or more One packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) oral granules  One packet (containing ivacaftor 75 mg) oral granules
6 to less than 12 years Less than 30 kg  Two tablets of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg)  One tablet of ivacaftor 75 mg
30 kg or more  Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) One tablet of ivacaftor 150 mg
12 years and older  – Two tablets of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg)  One tablet of ivacaftor 150 mg

Side effects:

  • Trikafta can cause serious liver damage and liver failure. 
  • Pain and discomfort in the abdominal area.
  • Yellowing eyes and skin.
  • Severe allergic reactions.
  • Abnormality of eye lens.

Storage: Store at 20 ºC – 25 ºC (68 ºF – 77 ºF)

  • Can cause serious liver damage, including liver failure and death.Monitor liver function (ALT, AST, bilirubin) before starting and regularly during treatment. Therefore, treatment is not recommended for hepatic impairment patients. 
  • May cause severe allergic reactions including anaphylaxis.
  • Lens opacities (cataracts) reported in children. Perform eye exams before and during treatment in pediatric patients.
  • Must be taken with a fat-containing meal to improve absorption.
  • Grapefruit and its juice can interfere with TRIKAFTA metabolism; avoid them

Process to Import Medicine

FAQ

Trikafta is used to treat cystic fibrosis (CF) in people aged 2 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene.

Trikafta combines three medicines—elexacaftor, tezacaftor, and ivacaftor—that help the faulty CFTR protein function more effectively, improving lung function and reducing mucus buildup.

It is approved for people 2 years and older with at least one copy of the F508del mutation or another mutation that responds to the medication.

Trikafta is taken orally as two tablets in the morning and one tablet in the evening, with fat-containing food.

Yes, a CFTR genetic test is required to confirm that the patient has a responsive mutation, such as F508del.

While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certification and possesses a valid operating license. These credentials confirm the supplier’s adherence to international standards for the proper distribution of medicinal products. 

The cost of Trikafta (Elexacaftor, Tezacaftor, and Ivacaftor) in India varies as the medicine is not locally manufactured and must be imported. Final pricing depends on supplier availability, import duties, and currency rates. For the latest cost details, contact 24/7QualityMeds at +91 9967979080.

To buy Trikafta (Elexacaftor, Tezacaftor, and Ivacaftor) online in India at a genuine price, contact 24/7QualityMeds. We assist patients with legal importation, ensure authenticity, and provide safe doorstep delivery.

Related products